623 related articles for article (PubMed ID: 23073759)
1. Role of epidermal growth factor receptor in breast cancer.
Masuda H; Zhang D; Bartholomeusz C; Doihara H; Hortobagyi GN; Ueno NT
Breast Cancer Res Treat; 2012 Nov; 136(2):331-45. PubMed ID: 23073759
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
3. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.
Mu Z; Klinowska T; Dong X; Foster E; Womack C; Fernandez SV; Cristofanilli M
J Exp Clin Cancer Res; 2014 May; 33(1):47. PubMed ID: 24886365
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of triple-negative breast cancer.
de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
[TBL] [Abstract][Full Text] [Related]
5. Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.
Inoue S; Patil R; Portilla-Arias J; Ding H; Konda B; Espinoza A; Mongayt D; Markman JL; Elramsisy A; Phillips HW; Black KL; Holler E; Ljubimova JY
PLoS One; 2012; 7(2):e31070. PubMed ID: 22355336
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.
Ferraro DA; Gaborit N; Maron R; Cohen-Dvashi H; Porat Z; Pareja F; Lavi S; Lindzen M; Ben-Chetrit N; Sela M; Yarden Y
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1815-20. PubMed ID: 23319610
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
[TBL] [Abstract][Full Text] [Related]
8. Targeting triple-negative breast cancer: optimising therapeutic outcomes.
Gelmon K; Dent R; Mackey JR; Laing K; McLeod D; Verma S
Ann Oncol; 2012 Sep; 23(9):2223-2234. PubMed ID: 22517820
[TBL] [Abstract][Full Text] [Related]
9. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
10. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.
Karihtala P; Auvinen P; Kauppila S; Haapasaari KM; Jukkola-Vuorinen A; Soini Y
Breast Cancer Res Treat; 2013 Feb; 138(1):81-90. PubMed ID: 23412770
[TBL] [Abstract][Full Text] [Related]
11. Developmental therapeutics for inflammatory breast cancer: Biology and translational directions.
Costa R; Santa-Maria CA; Rossi G; Carneiro BA; Chae YK; Gradishar WJ; Giles FJ; Cristofanilli M
Oncotarget; 2017 Feb; 8(7):12417-12432. PubMed ID: 27926493
[TBL] [Abstract][Full Text] [Related]
12. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
[TBL] [Abstract][Full Text] [Related]
13. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
Williams CB; Soloff AC; Ethier SP; Yeh ES
Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
[TBL] [Abstract][Full Text] [Related]
15. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
16. Promising therapeutic options in triple-negative breast cancer.
Bilici A; Arslan C; Altundag K
J BUON; 2012; 17(2):209-22. PubMed ID: 22740196
[TBL] [Abstract][Full Text] [Related]
17. EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray.
Liu D; He J; Yuan Z; Wang S; Peng R; Shi Y; Teng X; Qin T
Med Oncol; 2012 Jun; 29(2):401-5. PubMed ID: 21264531
[TBL] [Abstract][Full Text] [Related]
18. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
19. Novel targets for triple-negative breast cancer.
Carey LA
Clin Adv Hematol Oncol; 2011 Sep; 9(9):678-80. PubMed ID: 22402512
[No Abstract] [Full Text] [Related]
20. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
Liu T; Yacoub R; Taliaferro-Smith LD; Sun SY; Graham TR; Dolan R; Lobo C; Tighiouart M; Yang L; Adams A; O'Regan RM
Mol Cancer Ther; 2011 Aug; 10(8):1460-9. PubMed ID: 21690228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]